Discover the latest advancements in treating Type B aortic dissections and how endovascular interventions are seizing a critical window of opportunity to improve patient outcomes.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
An overview regarding the article ‘Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings.’.
Li et al., Curr Probl Cardiol 2024
DOI: 10.1016/j.cpcardiol.2024.102414
The abstract discusses the complex relationship between lung cancer and the development of atrial fibrillation (AF), highlighting the role of cancer-related inflammation, treatment, and comorbidities in atrial remodeling. It notes that while an association between AF and cancer has been recognized, it is not fully understood. Historical reports from the 1940s-50s first suggested a link through cardiac infiltration or mechanical pressure. More recent studies have shown an increased risk of AF post-cancer therapy, including surgery and chemotherapy. Interestingly, a higher prevalence of AF is observed in cancer patients even before treatment begins.
The field of cardio-oncology has emerged to explore the connections between cardiovascular disease and cancer, including the cardiovascular effects of cancer treatments, shared risk factors, and the impact of cardiac dysfunction on cancer progression. Regarding treatment for AF in cancer patients, direct oral anticoagulants (DOACs) are considered safe and effective compared to Vitamin K antagonists (VKAs), but this is primarily based on observational studies and sub-analyses of major DOAC trials.
Importance: This information is crucial for understanding the bidirectional relationship between cancer and AF, which may influence patient management and treatment decisions in the context of cardio-oncology.
Contribution to Literature: The abstract contributes to the literature by summarizing the historical and current understanding of the link between cancer and AF, and by emphasizing the need for more definitive research on the use of DOACs in cancer patients with AF.